GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioCryst Pharmaceuticals Inc (MEX:BCRX) » Definitions » Gross-Profit-to-Asset %

BioCryst Pharmaceuticals (MEX:BCRX) Gross-Profit-to-Asset % : 105.14% (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BioCryst Pharmaceuticals Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. BioCryst Pharmaceuticals's annualized Gross Profit for the quarter that ended in Dec. 2024 was MXN10,461 Mil. BioCryst Pharmaceuticals's average Total Assets over the quarter that ended in Dec. 2024 was MXN9,950 Mil. Therefore, BioCryst Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 105.14%.


BioCryst Pharmaceuticals Gross-Profit-to-Asset % Historical Data

The historical data trend for BioCryst Pharmaceuticals's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Gross-Profit-to-Asset % Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.44 32.85 45.21 56.89 96.19

BioCryst Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.68 73.34 96.04 97.86 105.14

Competitive Comparison of BioCryst Pharmaceuticals's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Gross-Profit-to-Asset % falls into.


;
;

BioCryst Pharmaceuticals Gross-Profit-to-Asset % Calculation

BioCryst Pharmaceuticals's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=9139.531/( (8775.007+10228.052)/ 2 )
=9139.531/9501.5295
=96.19 %

BioCryst Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=10461.468/( (9672.939+10228.052)/ 2 )
=10461.468/9950.4955
=105.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


BioCryst Pharmaceuticals Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.